These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 17094050)

  • 41. Autosomal dominant polycystic kidney disease: time for a change?
    Chapman AB
    J Am Soc Nephrol; 2007 May; 18(5):1399-407. PubMed ID: 17429048
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Progression of renal failure in the Han: SPRD polycystic kidney rat.
    Zeier M; Pohlmeyer G; Deerberg F; Schönherr R; Ritz E
    Nephrol Dial Transplant; 1994; 9(12):1734-9. PubMed ID: 7708256
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Inhibition of the renin-angiotensin system to prevent target organ damage: the "renal continuum"].
    Tislér A
    Orv Hetil; 2003 May; 144(18 Suppl 1):898-901. PubMed ID: 12785234
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Endothelin B receptor blockade accelerates disease progression in a murine model of autosomal dominant polycystic kidney disease.
    Chang MY; Parker E; El Nahas M; Haylor JL; Ong AC
    J Am Soc Nephrol; 2007 Feb; 18(2):560-9. PubMed ID: 17202412
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ambulatory blood pressure measurement in young normotensive patients with autosomal dominant polycystic kidney disease.
    de Almeida EA; de Oliveira EI; Lopes JA; Almeida AG; Lopes MG; Prata MM
    Rev Port Cardiol; 2007 Mar; 26(3):235-43. PubMed ID: 17549981
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of renin-angiotensin-aldosterone system and of sympathetic activity in arterial hypertension associated with autosomal dominant polycystic kidney disease.
    Cerasola G; Li Vecchi M; Mulé G; Cottone S; Mangano MT; Andronico G; Contomo A; Parrino IA; Renda F; Pavone G; Scialabba A
    Contrib Nephrol; 1997; 122():22-7. PubMed ID: 9399032
    [No Abstract]   [Full Text] [Related]  

  • 48. Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade.
    Griffin KA; Bidani AK
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1054-65. PubMed ID: 17699327
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Renin-Angiotensin-Aldosterone System Antagonism and Polycystic Kidney Disease Progression.
    Hian CK; Lee CL; Thomas W
    Nephron; 2016; 134(2):59-63. PubMed ID: 27476173
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease.
    Ecder T; Schrier RW
    Nat Rev Nephrol; 2009 Apr; 5(4):221-8. PubMed ID: 19322187
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade.
    Weir MR
    J Hum Hypertens; 2007 Oct; 21(10):770-9. PubMed ID: 17597800
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of VEGF polymorphism on progression of autosomal dominant polycystic kidney disease.
    Reiterová J; Obeidová H; Lenícek M; Stekrová J; Merta M; Maixnerová D; Vítek L; Viklický O; Tesar V
    Kidney Blood Press Res; 2008; 31(6):398-403. PubMed ID: 19060482
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of renin-angiotensin-aldosterone system gene polymorphisms and hypertension-induced end-stage renal disease in autosomal dominant polycystic kidney disease.
    Ramanathan G; Elumalai R; Periyasamy S; Lakkakula B
    Iran J Kidney Dis; 2014 Jul; 8(4):265-77. PubMed ID: 25001132
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Autosomal dominant polycystic kidney disease: new treatment options and how to test their efficacy.
    Wüthrich RP; Serra AL; Kistler AD
    Kidney Blood Press Res; 2009; 32(5):380-7. PubMed ID: 19887826
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members.
    Barrett BJ; Foley R; Morgan J; Hefferton D; Parfrey P
    Kidney Int; 1994 Oct; 46(4):1118-23. PubMed ID: 7861706
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [New therapies for ADPKD].
    Rathaus M
    G Ital Nefrol; 2007; 24(6):526-34. PubMed ID: 18278756
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiovascular complications in autosomal dominant polycystic kidney disease.
    Ecder T
    Curr Hypertens Rev; 2013 Feb; 9(1):2-11. PubMed ID: 23971638
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A promoter polymorphism of the alpha 8 integrin gene and the progression of autosomal-dominant polycystic kidney disease.
    Zeltner R; Hilgers KF; Schmieder RE; Porst M; Schulze BD; Hartner A
    Nephron Clin Pract; 2008; 108(3):c169-75. PubMed ID: 18277079
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Ambulatory 24-hour blood pressure monitoring of children and young adults with autosome dominant polycystic kidney degeneration].
    Geberth S; Zeier M; Schmidt KG; Mandelbaum A; Ritz E
    Z Kardiol; 1992; 81 Suppl 2():21-4. PubMed ID: 1514306
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis.
    Onuigbo MA; Onuigbo NT
    QJM; 2008 Jul; 101(7):519-27. PubMed ID: 18375475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.